GSK

Endometrial biopsy
#GSK #Oncology #Scottish Medicines Consortium (SMC) #Women's health

GSK’s endometrial cancer therapy approved in Scotland

The Scottish Medicines Consortium (SMC) has accepted GSK’s dostarlimab as a treatment for adult patients with endometrial cancer when used in combination with platinum-containing chemotherapy. Specifically, dostarlimab will be used for patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for… Read More

#News #Regulatory

Stamp of approval
#Blood cancer #GSK #MHRA #Oncology #Rare disease

JAK inhibitor for rare blood cancer approved in Great Britain

GSK’s Omjjara (momelotinib) has been granted marketing authorisation in Great Britain for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. It is approved in patients who are Janus kinase (JAK)… Read More

#News #Regulatory

GSK offices
#Asthma #GSK #Mergers and acquisitions #Monoclonal antibodies #Respiratory

GSK expands respiratory pipeline with Aiolos Bio acquisition

GSK is to acquire Aiolos Bio for a $1 billion upfront payment and up to $400 million in regulatory milestone payments. The acquisition includes Aiolos’ AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter Phase II clinical development for asthma, with potential for additional indications. Read More

#Business & Investment #News

Mosquito
#Bacteria #GSK #Malaria

Newly-discovered bacteria could prevent malaria

Research published in Science shows that a naturally occurring bacterium discovered by GSK scientists – Delftia tsuruhatensis Tres Cantos 1 (TC1) – could be the basis for new anti-malarial interventions. Studies done in collaboration at the Johns Hopkins Malaria Research Institute show that the bacterium can… Read More

#News

Endometrial cancer
#Cancer treatment #FDA #GSK #Oncology #Regulatory

FDA approves Jemperli plus chemo in endometrial cancer

GSK’s Jemperli (dostarlimab) has been approved in the US plus chemotherapy as the first new frontline treatment option in decades for primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). The US Food and Drug Administration (FDA) approved Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed… Read More

#News #Regulatory

#Acquisition #Biopharma #Biotechnology #CDMO #Cell and gene therapy #Cold chain #Drug development #GSK #Pfizer #Regulatory #Supply chain

New podcast: A business case for drug discovery

This is the latest episode of the free DDW narrated podcast, “A business case for drug discovery”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “A deal in the making”, “Why project management… Read More

#News

#AstraZeneca #Drug development #FDA #GSK #HER2 #National Institute for Health and Care Excellence (NICE) #Pfizer #Regulatory

New episode: DDW Highlights 19 June

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Regulatory approvals and industry guidelines are key to the continued development and discovery of drugs,… Read More

#News

#AstraZeneca #Drug development #FDA #GSK #HER2 #National Institute for Health and Care Excellence (NICE) #Pfizer #Regulatory

This week in drug discovery (12-16 June)  

News round-up for 5-9 June by DDW Multimedia Editor Megan Thomas.  Regulatory approvals and industry guidelines are key to the continued development and discovery of drugs, which is a common theme throughout this week’s news highlights, including an FDA approval for Pfizer, a NICE recommendation… Read More

#News

Respiratory syncytial virus
#FDA #GSK #Immunology / Virology & Vaccines #Pfizer #Respiratory syncytial virus

GSK faces RSV vaccine threat from rival Pfizer  

An FDA approval for Pfizer’s Abrysvo respiratory syncytial virus (RSV) vaccine is likely to threaten GSK’s current hold on the market, according to GlobalData.  GSK received approval by the European Commision (EC) for its vaccine Arexvy, which targets the prevention of lower respiratory tract infections (LRTI) caused by RSV in… Read More

#News #Regulatory #Trending News

Endometrial biopsy
#Cancer research #FDA #GSK #Immuno-oncology #Oncology #Phase I trial #Regulatory

Full FDA approval for endometrial cancer treatment

The US Food and Drug Administration (FDA) has granted full approval for Jemperli (dostarlimab-gxly) for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, as determined by a US FDA-approved test.  The approval is for endometrial cancer that has progressed on or following a prior… Read More

#News #Regulatory

Diversity
#Clinical research #Clinical trial design #Clinical trials #Diversity #Epidemiology #GSK #United States

Study shines a light on representation in clinical research

A diversity study has shown that clinical trials should use real world diseases epidemiology data, rather than US Census Bureau race and ethnicity data, to ensure enrolment reflects the populations affected by different diseases.  GSK’s retrospective study looked at clinical trial demographic data from 495 GSK and… Read More

#Editor's Choice #News

Patient receiving dialysis treatment
#Chronic kidney disease (CKD) #FDA #GSK #Kidney disease

New oral option for anaemia of CKD approved in US

The US Food and Drug Administration (FDA) has approved Jesduvroq (daprodustat) for the once-a-day treatment of anaemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months.   Jesduvroq is the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) approved in the US. … Read More

#News #Regulatory

Patient taking antibiotics
#Antibiotics #GSK #Phase II trial #TB #Tuberculosis

New class of antibiotics could help address the TB epidemic 

A first-in-class investigational antitubercular agent has shown early bactericidal activity with a low, once-daily oral dose after 14 days of treatment.  The Phase IIa study evaluated GSK’s GSK3036656 in participants with drug-susceptible pulmonary tuberculosis. The company hopes GSK3036656 could be a component of simpler treatment regimens in… Read More

#News #Trending News

#Business #GSK #Immunology / Virology & Vaccines #Pharmaceuticals

GSK reports strong Q3 results  

GSK has announced strong quarterly results, reporting sales of £7.8 billion and growth in various sectors of the business.   Overall, the company’s adjusted operating profit for the third quarter came in at £2.6 billion, a 17% increase compared to the same period last year and reflecting a 4% year-on-growth at… Read More

#Business & Investment

Shingles
#Clinical trial #GSK #Immunology / Virology & Vaccines #Recombinant Zoster Vaccine #Shingles

Shingles vaccine provides protection for a decade

New data have shown that GSK’s Shingrix provides at least 10 years of protection against shingles in adults aged 50 years and over. In the primary endpoint, the interim data demonstrated overall efficacy of greater than 80% over the follow-up period of approximately six to 10 years after initial vaccination. Read More

#News